Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPS804 in Adult Osteogenesis Imperfecta
NCT03216486Phase 2Withdrawn
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of setrusumab in osteogenesis imperfecta (OI), sponsored by Ultragenyx Pharmaceutical Inc.. Planned start Oct 2017; status: withdrawn.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT03216486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216486.